Gilead Opens Access To HIV Treatments | Chemical & Engineering News
Volume 89 Issue 29 | p. 18 | Concentrates
Issue Date: July 18, 2011

Gilead Opens Access To HIV Treatments

Department: Business
Keywords: HIV, AIDS, patent pool

Gilead Sciences has expanded access to its HIV medicines through agreements with the Medicines Patent Pool Foundation (MPPF), a nonprofit supported by UNITAIDand the Indian drug firms Hetero Drugs, Matrix Laboratories, Ranbaxy Laboratories, and Strides Arcolab. Both MPPF and the companies gain the right to produce for the developing world three drugs in late-stage clinical trials: elvitegravir, an integrase inhibitor; cobicistat, an antiretroviral boosting agent; and the Quad, which combines four Gilead HIV medicines in a once-daily pill. In 2006, Gilead allowed several manufacturers to make generic versions of the HIV drugs Viread and Truvada.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment